Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study
Annals of Transplantation · 2023
DOI: 10.12659/aot.941346 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Transplantation, 2023. Verfasst von Kohei Ogawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Toon, Ehime, Japan. Hauptthemen laut MEDLINE: Living Donors, Liver Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND In liver transplantation (LT), preoperative desensitization therapy is considered necessary in patients positive for donor-specific anti-human leukocyte antigen antibodies (DSAs). However, the relationship between DSA intensity and the necessary desensitization therapy is unclear. MATERIAL AND METHODS A total of 37 adult living donor (LD) LTs performed between January 2016 and March 2022 were examined. Mycophenolate mofetil (MMF) was administered preoperatively in DSA-positive cases with positive lymphocyte cross-matching who underwent LDLT. In those with strongly positive DSA (mean fluorescence intensity 10 000), rituximab was administered 2 weeks before LDLT in addition to MMF. Cross-reactive epitope group antigen (CREG)-alone-positive cases were also treated with preoperative MMF when lymphocyte cross-matching was positive. RESULTS Of the 37 patients, 9 were DSA-positive, 7 were CREG-alone-positive, and the others were double-negative. Of 9 DSA-positive cases, desensitization therapy was performed in 7, among which rituximab administration was performed in 3 strongly DSA-positive cases. Of 7 CREG-alone-positive cases, 2 were lymphocyte cross-match-positive and underwent desensitization therapy. The 1-year survival rate was 100% in both DSA- and CREG-alone-positive cases. The frequency of T-cell mediated rejection in DSA-positive, CREG-alone-positive, and double-negative cases was 22%, 43%, and 29%, respectively, with no significant difference. Antibody-mediated rejection occurred in only 1 patient, who was strongly DSA-positive and blood-group incompatible. There was also no significant difference among the 3 groups in terms of the frequency of biliary complications or 90-day mortality. CONCLUSIONS Satisfactory LDLT results were achieved in DSA- and CREG-alone-positive cases following desensitization therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic and Breast Surgery, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
ORCID-Profile: Kohei Ogawa, Kei Tamura, Katsunori Sakamoto, Naotake Funamizu, Masahiko Honjo, Tomoyuki Nagaoka, Yasutsugu Takada
Zitieren
APA
Ogawa, K., Tamura, K., Sakamoto, K., Funamizu, N., Honjo, M., Shine, M., Nishi, Y., Nagaoka, T., Ito, C., Iwata, M., Uraoka, M., & Takada, Y. (2023). Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study. Annals of Transplantation. https://doi.org/10.12659/aot.941346
Vancouver
Ogawa K, Tamura K, Sakamoto K, Funamizu N, Honjo M, Shine M, et al. Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study. Annals of Transplantation. 2023. doi:10.12659/aot.941346
BibTeX
@article{Ogawa2023,
author = {Ogawa, Kohei and Tamura, Kei and Sakamoto, Katsunori and Funamizu, Naotake and Honjo, Masahiko and Shine, Mikiya and Nishi, Yusuke and Nagaoka, Tomoyuki and Ito, Chihiro and Iwata, Miku and Uraoka, Mio and Takada, Yasutsugu},
title = {Living Donor Liver Transplantation in Patients with Preformed Donor-Specific Anti-Human Leukocyte Antigen Antibodies Using Preoperative Desensitization Therapy According to Intensity of Donor-Specific Antibodies: A Single-Center Study},
journal = {Annals of Transplantation},
year = {2023},
doi = {10.12659/aot.941346}
}
EUVIMED